Metronomic therapy has low toxicity and is as effective as
current standard treatment for recurrent high-risk
neuroblastoma

J 2017

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA et. al.

Basic information

Original name

Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma

Authors

BERTHOLD, Frank (276 Germany, guarantor), Marc HÖMBERG (276 Germany), Inna PROLESKOVSKAJA (112 Belarus), Pavel MAZÁNEK (203 Czech Republic, belonging to the institution), Margarita BELOGUROVA (643 Russian Federation), Angela ERNST (276 Germany) and Jaroslav ŠTĚRBA (203 Czech Republic, belonging to the institution)

Edition

Pediatric Hematology and Oncology, Philadelphia, Taylor & Francis, 2017, 0888-0018

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.154

RIV identification code

RIV/00216224:14110/17:00102137

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/08880018.2017.1373314

UT WoS

000419983600006

Keywords in English

Angiogenesis; dose-intense chemotherapy; immunomodulation; metronomic therapy; neuroblastoma

Abstract

V originále

The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.

Citovat

BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA, Angela ERNST and Jaroslav ŠTĚRBA. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric Hematology and Oncology. Philadelphia: Taylor & Francis, 2017, vol. 34, No 5, p. 308-319. ISSN 0888-0018. Available from: https://dx.doi.org/10.1080/08880018.2017.1373314.

@article{1399419,
   author = {Berthold, Frank and Hömberg, Marc and Proleskovskaja, Inna and Mazánek, Pavel and Belogurova, Margarita and Ernst, Angela and Štěrba, Jaroslav},
   article_location = {Philadelphia},
   article_number = {5},
   doi = {http://dx.doi.org/10.1080/08880018.2017.1373314},
   keywords = {Angiogenesis; dose-intense chemotherapy; immunomodulation; metronomic therapy; neuroblastoma},
   language = {eng},
   issn = {0888-0018},
   journal = {Pediatric Hematology and Oncology},
   title = {Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma},
   volume = {34},
   year = {2017}
}

TY  - JOUR
ID  - 1399419
AU  - Berthold, Frank - Hömberg, Marc - Proleskovskaja, Inna - Mazánek, Pavel - Belogurova, Margarita - Ernst, Angela - Štěrba, Jaroslav
PY  - 2017
TI  - Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma
JF  - Pediatric Hematology and Oncology
VL  - 34
IS  - 5
SP  - 308-319
EP  - 308-319
PB  - Taylor & Francis
SN  - 08880018
KW  - Angiogenesis
KW  - dose-intense chemotherapy
KW  - immunomodulation
KW  - metronomic therapy
KW  - neuroblastoma
N2  - The metronomic therapy concept uses low doses of continuously applied chemotherapeutic, anti-angiogenetic, and immunomodulating drugs. Twenty patients with recurrent and 3 with refractory high-risk neuroblastoma were treated by the metronomic concept using celecoxib, cyclophosphamide, vinblastine, and etoposide for up to 24 months. The outcome was compared to 274 matched patients with a first recurrence from stage 4 neuroblastoma using the variables time from diagnosis to first recurrence, number of organs involved, and MYCN amplification. All were treated with dose-intensive conventional chemotherapy. The study patients experienced 1-3 recurrences and had 1-3 sites involved (osteomedullary, primary tumor, central nervous system, lymph nodes, liver, lungs) before the metronomic therapy started. Two patients in complete remission and three with active refractory disease following recurrence treatment were excluded from the outcome analysis. The curves for secondary event-free and overall survival demonstrated no significant differences.
ER  -

BERTHOLD, Frank, Marc HÖMBERG, Inna PROLESKOVSKAJA, Pavel MAZÁNEK, Margarita BELOGUROVA, Angela ERNST and Jaroslav ŠTĚRBA. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. \textit{Pediatric Hematology and Oncology}. Philadelphia: Taylor \&{} Francis, 2017, vol.~34, No~5, p.~308-319. ISSN~0888-0018. Available from: https://dx.doi.org/10.1080/08880018.2017.1373314.

Detailed Information on Publication Record